XOMA to Present New Strategic Initiatives at the Cowen and Company 37th Annual Health Care Conference

BERKELEY, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- XOMA Corporation XOMA, a leader in the discovery and development of therapeutic antibodies, announced today that Jim Neal, Chief Executive Officer, will present the company's new strategic initiatives and value drivers at the Cowen and Company 37^th Annual Health Care Conference on Tuesday, March 7, 2017 at 11:20 a.m. ET. The conference is being held at the Boston Marriott Copley Place hotel.

A live audio webcast of the presentation can be accessed in the Investors and Media section of XOMA's website at http://investors.xoma.com/events.cfm. An archived version of the webcast will be available via replay for 90 days following the presentation.

About XOMA Corporation

XOMA discovers and develops innovative antibody therapeutics. XOMA has an extensive portfolio of products, programs, and technologies that are the subject of licenses the company has in place with other biotech and pharmaceutical companies. There are more than 20 such programs that are fully funded by partners and could produce milestone payments and royalty payments in the future. XOMA continues to advance Phase 2 development activities for 358, an allosteric monoclonal antibody that reduces insulin receptor activity, as the antibody could have a major impact on the treatment of hyperinsulinism, particularly congenital hyperinsulinism and hypoglycemia after bariatric surgery. For more information, visit www.xoma.com.

CONTACTS:

Investor contact:
Luke Heagle
Pure Communications
+1 910-726-1372
lheagle@purecommunications.com

Media contact:
Colin Sanford
Pure Communications
+1 415-946-1094
csanford@purecommunications.com